-
Keymed Biosciences’ CM310 Achieves Primary Endpoints in Phase III Atopic Dermatitis Study
•
China-based Keymed Biosciences Inc., a prominent player in the biopharmaceutical industry (HKG: 2162), has announced that its IL-4Rα monoclonal antibody (mAb) drug candidate, CM310, has successfully reached its primary endpoints in a confirmatory Phase III clinical study for the treatment of moderate to severe atopic dermatitis (AD). Phase III Study…
-
Broncus Medical and Venus Medtech Establish Joint Venture Fund for Digital Medical Equipment
•
Broncus Medical Inc., (HKG: 2216) a leading provider of lung disease precision intervention solutions based in China, has joined forces with Venus Medtech (Hangzhou) Inc., another prominent player in the medical field (HKG: 2500), to announce the establishment of a partnership fund. Each company is contributing RMB 125 million (USD…
-
AstraZeneca Plans Tripled R&D Investment in China, Aims for 15 New Drugs by 2030
•
At the AstraZeneca’s (AZ, NASDAQ: AZN) R&D China Science Day, Yicai Global reported that the UK-based pharmaceutical giant is planning to triple its investment in research and development in China over the coming months. This strategic move aims to increase the number of innovative drugs entering the Chinese market, as…
-
Burning Rock Reports Q4 2022 Revenue Dip but 10.9% Full-Year Growth
•
Guangzhou-based medical device company Burning Rock (NASDAQ: BNR) has released its financial results for the fourth quarter of 2022. The company reported Q4 revenues of CNY 142.2 million (USD 20.6 million), marking a 3.5% decrease year-on-year (YOY). However, for the full 12 months, revenues showed a positive trend, increasing by…
-
CDE Grants Priority Review Status to TQB3454, HLX208, and Infigratinib for Cancer Treatments
•
The Center for Drug Evaluation (CDE) website has indicated that Chia Tai Tianqing’s TQB3454, Henlius Bio’s HLX208, and LianBio’s infigratinib are all set to be awarded priority review status as Category 1 chemical drugs. TQB3454: A Promising IDH1 Mutase InhibitorTQB3454 is an in-house developed IDH1 mutase inhibitor intended for the…
-
Brii Biosciences Halts Development of Antibody Cocktail for COVID-19 Treatment
•
Brii Biosciences has announced a strategic decision to end the manufacturing and further development of the amubarvimab/romlusevimab combination treatment regimen for COVID-19. According to the company’s recent 2022 financial report, the antibody cocktail had been commercially available in China from July 2022 following an emergency use authorization (EUA) and had…
-
Berry Genomics Partners with MGI Tech to Advance Cancer Diagnostics and Screening
•
Chengdu-based Berry Genomics Co., Ltd has announced a strategic partnership with MGI Tech, a subsidiary of BGI Group (SHE: 300676), based in China. The collaboration aims to localize and transform comprehensive cancer care by introducing automation platforms for sequencing pipelines across the entire cycle of precise diagnosis and treatment of…
-
PharmaBlock Expands US Presence with New R&D Facility in West Chester
•
PharmaBlock, a leading company based in Nanjing (SHE: 300725), has announced the opening of a new R&D facility in West Chester, Pennsylvania. This strategic move aims to expand the company’s presence in the United States and offer more efficient process R&D services, enabling the fast delivery of clinical-stage GMP projects…
-
CSPC Pharmaceutical Receives NMPA Approval for Generic Otezla Equivalent
•
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that its generic version of Celgene’s Otezla (apremilast) has obtained marketing approval from the National Medical Products Administration (NMPA), signifying that it has passed the generic quality and efficacy consistency evaluation. Apremilast’s Background and Clinical Necessity in ChinaApremilast, an oral small…
-
BJ Bioscience Partners with MSD for Phase I Clinical Trial of BJ-001 and Keytruda
•
Shanghai-based biotech BJ Bioscience Inc. has announced a clinical trial collaboration and supply agreement with Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK). This strategic partnership will see the combination of BJ Bio’s pipeline candidate, BJ-001, with MSD’s programmed death-1 (PD-1) inhibitor, Keytruda (pembrolizumab), in a Phase I clinical trial…
-
Acotec Scientific’s Vericor Receives Marketing Approval from Thailand FDA
•
China-based Acotec Scientific Holdings Ltd (HKG: 6669) has announced that it has received marketing approval for its Vericor peripheral support catheter from the Thailand Food and Drug Administration. This development marks a significant step for the company as it expands the reach of its medical devices in the Southeast Asian…
-
CANbridge Pharmaceuticals Completes Enrollment in Phase II GBM Trial for CAN008
•
Sino-US biopharma CANbridge Pharmaceuticals (HKG: 1228) has announced the completion of patient enrollment in a Phase II trial for its pipeline candidate CAN008 (asunercept) in combination with temozolomide for the treatment of glioblastoma multiforme (GBM). The multi-center, randomized, placebo-controlled study, which is potentially registrational, has recruited a total of 117…
-
Chongqing Genrix’s Xeligekimab for Psoriasis Accepted for Market Approval Review
•
China-based Chongqing Genrix Biopharmaceutical Co., Ltd (SHA: 688443) has announced that the market approval filing for its in-house developed Category 1 biological product, Xeligekimab, for the treatment of moderate to severe plaque psoriasis has been accepted for review. This development marks a significant step forward for the company and the…
-
Hansoh Pharmaceutical Reports 2022 Revenues and Highlights Growth in Innovative Drugs
•
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has released its financial report for 2022. As of December 31, 2022, the company reported revenues of RMB 9.382 billion (USD 1.362 billion), a decrease of 5.6% year-on-year (YOY). Despite this, the sales revenue of innovative drugs reached RMB 5.006 billion (USD…
-
Fosun Pharma Reports 12.66% YOY Revenue Growth and Increased R&D Investment in 2022 Financial Report
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has released its financial report for 2022, highlighting revenues of RMB 43.952 billion (USD 6.381 billion), marking a 12.66% increase year-on-year (YOY). The company’s net profits also saw a significant rise, reaching RMB 3.873 billion (USD 562.4 million), up 18.17%…
-
CSPC Pharmaceutical’s mRNA Vaccine SYS6006 Receives Emergency Use Authorization in China
•
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has obtained an Emergency Use Authorization (EUA) for its in-house developed COVID-19 mRNA vaccine, SYS6006, in China. This approval marks a significant milestone as it is the first for a domestically developed mRNA product in the country. Design and…
-
Boston Scientific Launches Athletis Peripheral Balloon Dilatation Catheter in China
•
US-based medical device leader, Boston Scientific Corporation (NYSE: BSX), has announced the market launch of its Athletis peripheral balloon dilatation catheter in mainland China. The product is designed for percutaneous transluminal angioplasty (PTA) of the peripheral vascular system and is utilized in the treatment of stenotic lesions in autologous or…
-
Huarun Pharmaceutical Co., Ltd Announces Private Placement to Fund Expansion and R&D
•
China-based Huaren Pharmaceutical Co., Ltd (SHE: 300110) is set to raise capital through the private placement of 355 million shares, aiming to collect RMB 1.34 billion (USD 194.8 million). The funds procured will be allocated towards several key projects, including the expansion of peritoneal dialysate production capacity, the construction of…
-
Zhaoke Ophthalmology Signs Distribution Agreement with Kwangdong for NVK002 in South Korea
•
China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) subsidiary Zhaoke Ophthalmology Ltd (HKG: 6622) has announced a distribution and supply agreement with South Korea’s Kwangdong Pharmaceutical Co., Ltd for NVK002, an atropine external use eye solution. Under the terms of the agreement, Kwangdong will assume import, publicity, distribution, marketing, and sales…
-
Sihuan Pharmaceutical’s XZP-KM602 and XZP-6877 Gain Clinical Trial Approvals
•
China-based Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced that its minority-owned subsidiary, Xuanzhu Biopharmaceutical Co., Ltd, has obtained clinical trial approvals for two in-house developed drugs: CD80 mutant Fc fusion protein XZP-KM602 and DNA dependent protein kinase (DNA-PK) inhibitor XZP-6877. Both drugs are aimed at treating advanced solid…
